Jaymin Kang

Philadelphia

Drug Information Specialist at The Cardiology Advisor

Drug Information Specialist at Monthly Prescribing Reference

Featured in: Favicon

empr.com

thecardiologyadvisor.com Favicon

clinicaladvisor.com Favicon

psychiatryadvisor.com Favicon

cancertherapyadvisor.com Favicon

renalandurologynews.com Favicon

endocrinologyadvisor.com Favicon

neurologyadvisor.com Favicon

infectiousdiseaseadvisor.com Favicon

dermatologyadvisor.com + 6 more

Articles

FDA Approves Freeze-Dried Formulation of Mpox, Smallpox Vaccine

2 weeks ago | dermatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved a new freeze-dried formulation of Jynneos® (smallpox and mpox vaccine, live, non-replicating). Prior to this approval, Jynneos had only been available as a liquid-frozen formulation. Jynneos was approved in 2019 for the prevention of smallpox and mpox disease in adults 18 years of age and older at high risk for smallpox or mpox infection.
Vanrafia Gets Accelerated Approval for Immunoglobulin A Nephropathy

2 weeks ago | rheumatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5g/g. The pathogenesis of IgAN is believed to be driven by the endothelin (ET)-1 peptide through the ETA receptor.
Setmelanotide Reduces BMI in Patients With Acquired Hypothalamic Obesity

2 weeks ago | empr.com | Jaymin Kang

Topline data were announced from a phase 3 trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity.
Uplizna Approved to Treat Immunoglobulin G4-Related Disease

2 weeks ago | empr.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Uplizna® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.
FDA Approves Freeze-Dried Formulation of Mpox, Smallpox Vaccine

3 weeks ago | rheumatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved a new freeze-dried formulation of Jynneos® (smallpox and mpox vaccine, live, non-replicating). Prior to this approval, Jynneos had only been available as a liquid-frozen formulation. Jynneos was approved in 2019 for the prevention of smallpox and mpox disease in adults 18 years of age and older at high risk for smallpox or mpox infection.
Daridorexant Improves Sleep, Comorbid Nocturia in Patients With Insomnia

3 weeks ago | psychiatryadvisor.com | Jaymin Kang

Daridorexant was associated with improvements in both insomnia and comorbid nocturia in adults aged 55 years and older, according to a study published in the Journal of Sleep Research. Daridorexant, a dual orexin receptor antagonist, is currently approved under the brand name Quviviq™ for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Tau-Targeting Antisense Therapy for Alzheimer Disease Gets Fast Track Status

3 weeks ago | clinicaladvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080 for the treatment of Alzheimer disease (AD). Abnormal accumulation of tau protein in the brain has been associated with neurodegeneration and cognitive decline in AD patients. BIIB080 is an investigational antisense oligonucleotide therapy that targets microtubule-associated protein tau mRNA preventing the production of the disease-causing protein.
Vanrafia Gets Accelerated Approval for Immunoglobulin A Nephropathy

3 weeks ago | renalandurologynews.com | Jaymin Kang

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5g/g. The pathogenesis of IgAN is believed to be driven by the endothelin (ET)-1 peptide through the ETA receptor.
FDA Approves Freeze-Dried Formulation of Mpox, Smallpox Vaccine

3 weeks ago | clinicaladvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved a new freeze-dried formulation of Jynneos® (smallpox and mpox vaccine, live, non-replicating). Prior to this approval, Jynneos had only been available as a liquid-frozen formulation. Jynneos was approved in 2019 for the prevention of smallpox and mpox disease in adults 18 years of age and older at high risk for smallpox or mpox infection.
Letybo Now Available for Moderate to Severe Glabellar Lines

3 weeks ago | dermatologyadvisor.com | Jaymin Kang

Letybo® (letibotulinumtoxinA-wlbg) is now available for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.